Advances in multidisciplinary therapy for meningiomas

International Consortium on Meningiomas

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Surgery has long been established as the first-line treatment for the majority of symptomatic and enlarging meningiomas, and evidence for its success is derived from retrospective case series. Despite surgical resection, a subset of meningiomas display aggressive behavior with early recurrences that are difficult to treat. The decision to radically resect meningiomas and involved structures is balanced against the risk for neurological injury in patients. Radiation therapy has largely been used as a complementary and safe therapeutic strategy in meningiomas with evidence primarily stemming from retrospective, single-Institution reports. Two of the first cooperative group studies (RTOG 0539 and EORTC 22042) evaluating the outcomes of adjuvant radiation therapy in higher-risk meningiomas have shown promising preliminary results. Historically, systemic therapy has resulted in disappointing results in meningiomas. However, several clinical trials are under way evaluating the efficacy of chemotherapies, such as trabectedin, and novel molecular agents targeting Smoothened, AKT1, and focal adhesion kinase in patients with recurrent meningiomas.

Original languageEnglish (US)
Pages (from-to)I18-I31
JournalNeuro-oncology
Volume21
DOIs
StatePublished - Jan 14 2019

Fingerprint

Meningioma
trabectedin
Therapeutics
Radiotherapy
Focal Adhesion Protein-Tyrosine Kinases
Clinical Trials
Recurrence
Drug Therapy
Wounds and Injuries

Keywords

  • clinical trial
  • meningioma
  • radiation
  • surgery
  • targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research

Cite this

International Consortium on Meningiomas. / Advances in multidisciplinary therapy for meningiomas. In: Neuro-oncology. 2019 ; Vol. 21. pp. I18-I31.
@article{948cd3c59f6e4089b95a4e4d88c4c59b,
title = "Advances in multidisciplinary therapy for meningiomas",
abstract = "Surgery has long been established as the first-line treatment for the majority of symptomatic and enlarging meningiomas, and evidence for its success is derived from retrospective case series. Despite surgical resection, a subset of meningiomas display aggressive behavior with early recurrences that are difficult to treat. The decision to radically resect meningiomas and involved structures is balanced against the risk for neurological injury in patients. Radiation therapy has largely been used as a complementary and safe therapeutic strategy in meningiomas with evidence primarily stemming from retrospective, single-Institution reports. Two of the first cooperative group studies (RTOG 0539 and EORTC 22042) evaluating the outcomes of adjuvant radiation therapy in higher-risk meningiomas have shown promising preliminary results. Historically, systemic therapy has resulted in disappointing results in meningiomas. However, several clinical trials are under way evaluating the efficacy of chemotherapies, such as trabectedin, and novel molecular agents targeting Smoothened, AKT1, and focal adhesion kinase in patients with recurrent meningiomas.",
keywords = "clinical trial, meningioma, radiation, surgery, targeted therapy",
author = "{International Consortium on Meningiomas} and Brastianos, {Priscilla K.} and Evanthia Galanis and Nicholas Butowski and Chan, {Jason W.} and Dunn, {Ian F.} and Roland Goldbrunner and Christel Herold-Mende and Ippen, {Franziska M.} and Christian Mawrin and McDermott, {Michael W.} and Andrew Sloan and James Snyder and Ghazaleh Tabatabai and Marcos Tatagiba and Tonn, {Joerg C.} and Wen, {Patrick Y.} and Kenneth Aldape and Farshad Nassiri and Gelareh Zadeh and Jenkinson, {Michael D.} and Raleigh, {David R.} and Karolyn Au and Jill Barnhartz-Sloan and Bi, {Wenya Linda} and Carlos Carlotti and Cusimano, {Michael D.} and Francesco Dimeco and Katharine Drummond and Caterina Giannini and Brent Griffith and Rintaro Hashizume and Hanemann, {C. Oliver} and Horbinski, {Craig Michael} and Huang, {Raymond Y.} and David James and Christine Jungk and Kaufman, {Timothy J.} and Boris Krischek and Daniel Lachance and Christian Lafoug{\`e}re and Ian Lee and Liu, {Jeff C.} and Yasin Mamatjan and Alireza Mansouri and David Munoz and Houtan Noushmehr and Ng, {Ho Keung} and Arie Perry and Farhad Pirouzmand and Poisson, {Laila M.}",
year = "2019",
month = "1",
day = "14",
doi = "10.1093/neuonc/noy136",
language = "English (US)",
volume = "21",
pages = "I18--I31",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",

}

International Consortium on Meningiomas 2019, 'Advances in multidisciplinary therapy for meningiomas', Neuro-oncology, vol. 21, pp. I18-I31. https://doi.org/10.1093/neuonc/noy136

Advances in multidisciplinary therapy for meningiomas. / International Consortium on Meningiomas.

In: Neuro-oncology, Vol. 21, 14.01.2019, p. I18-I31.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Advances in multidisciplinary therapy for meningiomas

AU - International Consortium on Meningiomas

AU - Brastianos, Priscilla K.

AU - Galanis, Evanthia

AU - Butowski, Nicholas

AU - Chan, Jason W.

AU - Dunn, Ian F.

AU - Goldbrunner, Roland

AU - Herold-Mende, Christel

AU - Ippen, Franziska M.

AU - Mawrin, Christian

AU - McDermott, Michael W.

AU - Sloan, Andrew

AU - Snyder, James

AU - Tabatabai, Ghazaleh

AU - Tatagiba, Marcos

AU - Tonn, Joerg C.

AU - Wen, Patrick Y.

AU - Aldape, Kenneth

AU - Nassiri, Farshad

AU - Zadeh, Gelareh

AU - Jenkinson, Michael D.

AU - Raleigh, David R.

AU - Au, Karolyn

AU - Barnhartz-Sloan, Jill

AU - Bi, Wenya Linda

AU - Carlotti, Carlos

AU - Cusimano, Michael D.

AU - Dimeco, Francesco

AU - Drummond, Katharine

AU - Giannini, Caterina

AU - Griffith, Brent

AU - Hashizume, Rintaro

AU - Hanemann, C. Oliver

AU - Horbinski, Craig Michael

AU - Huang, Raymond Y.

AU - James, David

AU - Jungk, Christine

AU - Kaufman, Timothy J.

AU - Krischek, Boris

AU - Lachance, Daniel

AU - Lafougère, Christian

AU - Lee, Ian

AU - Liu, Jeff C.

AU - Mamatjan, Yasin

AU - Mansouri, Alireza

AU - Munoz, David

AU - Noushmehr, Houtan

AU - Ng, Ho Keung

AU - Perry, Arie

AU - Pirouzmand, Farhad

AU - Poisson, Laila M.

PY - 2019/1/14

Y1 - 2019/1/14

N2 - Surgery has long been established as the first-line treatment for the majority of symptomatic and enlarging meningiomas, and evidence for its success is derived from retrospective case series. Despite surgical resection, a subset of meningiomas display aggressive behavior with early recurrences that are difficult to treat. The decision to radically resect meningiomas and involved structures is balanced against the risk for neurological injury in patients. Radiation therapy has largely been used as a complementary and safe therapeutic strategy in meningiomas with evidence primarily stemming from retrospective, single-Institution reports. Two of the first cooperative group studies (RTOG 0539 and EORTC 22042) evaluating the outcomes of adjuvant radiation therapy in higher-risk meningiomas have shown promising preliminary results. Historically, systemic therapy has resulted in disappointing results in meningiomas. However, several clinical trials are under way evaluating the efficacy of chemotherapies, such as trabectedin, and novel molecular agents targeting Smoothened, AKT1, and focal adhesion kinase in patients with recurrent meningiomas.

AB - Surgery has long been established as the first-line treatment for the majority of symptomatic and enlarging meningiomas, and evidence for its success is derived from retrospective case series. Despite surgical resection, a subset of meningiomas display aggressive behavior with early recurrences that are difficult to treat. The decision to radically resect meningiomas and involved structures is balanced against the risk for neurological injury in patients. Radiation therapy has largely been used as a complementary and safe therapeutic strategy in meningiomas with evidence primarily stemming from retrospective, single-Institution reports. Two of the first cooperative group studies (RTOG 0539 and EORTC 22042) evaluating the outcomes of adjuvant radiation therapy in higher-risk meningiomas have shown promising preliminary results. Historically, systemic therapy has resulted in disappointing results in meningiomas. However, several clinical trials are under way evaluating the efficacy of chemotherapies, such as trabectedin, and novel molecular agents targeting Smoothened, AKT1, and focal adhesion kinase in patients with recurrent meningiomas.

KW - clinical trial

KW - meningioma

KW - radiation

KW - surgery

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85060012470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060012470&partnerID=8YFLogxK

U2 - 10.1093/neuonc/noy136

DO - 10.1093/neuonc/noy136

M3 - Article

C2 - 30649489

AN - SCOPUS:85060012470

VL - 21

SP - I18-I31

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

ER -